/

Other

/

Adalvo

Adalvo

Adalvo

Verified Nov 2026

Other

·

San Gwann

·

Since 2020

Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.

Adalvo

Verified Nov 2026

AT A GLANCE

Founded

2020

Headquarters

San Gwann

Employees

200-500

Ownership

Adalvo at a glance

Revenue

$100-250M

Est. band

Employees

200-500

Founded

2020

Headquarters

San Gwann

Industries

Automotive

Electric Vehicles

Medical

Industrial Equipment

Overview

Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.

At a glance

Attribute

Detail

Founded

2020

Headquarters

San Gwann

Employees

200-500

Revenue

$100-250M (estimated)

What Adalvo makes

The company manufactures generic pharmaceuticals, peptides, and biosimilar products including Azelastine/Fluticasone nasal spray and Cladribine tablets, with a focus on regulatory approval and commercialization services.

Latest developments

Company details

Adalvo operates as a private company with partnerships spanning over 140 countries, serving large pharmaceutical manufacturers and commercial partners across multiple therapeutic areas. Adalvo was founded in 2020, has an estimated 200-500 employees, and is headquartered in San Gwann.

Frequently asked questions

What does Adalvo do?

Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.

Where is Adalvo headquartered?

Adalvo is headquartered in San Gwann.

When was Adalvo founded?

Adalvo was founded in 2020.

How big is Adalvo?

Adalvo has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

San GwannHeadquarters · San Gwann, Malta
San GwannSan Gwann, MaltaHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.